BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 10894262)

  • 1. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
    Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
    J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
    Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
    Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
    Eke GH; Iscan A; Cece H; Calik M
    Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease.
    McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P
    Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspartoacylase gene knockout in the mouse: impact on reproduction.
    Surendran S; Szucs S; Tyring SK; Matalon R
    Reprod Toxicol; 2005; 20(2):281-3. PubMed ID: 15907664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canavan disease: a review of recent developments.
    Gordon N
    Eur J Paediatr Neurol; 2001; 5(2):65-9. PubMed ID: 11589315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canavan disease: genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution.
    Kaul R; Balamurugan K; Gao GP; Matalon R
    Genomics; 1994 May; 21(2):364-70. PubMed ID: 8088831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canavan disease and the role of N-acetylaspartate in myelin synthesis.
    Namboodiri AM; Peethambaran A; Mathew R; Sambhu PA; Hershfield J; Moffett JR; Madhavarao CN
    Mol Cell Endocrinol; 2006 Jun; 252(1-2):216-23. PubMed ID: 16647192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
    Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ
    Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
    Unalp A; Altiok E; Uran N; Oztürk A; Yüksel S
    J Trop Pediatr; 2008 Jun; 54(3):208-10. PubMed ID: 17999961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspartoacylase gene knockout results in severe vacuolation in the white matter and gray matter of the spinal cord in the mouse.
    Surendran S; Campbell GA; Tyring SK; Matalon R
    Neurobiol Dis; 2005 Mar; 18(2):385-9. PubMed ID: 15686967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse neural progenitor cells differentiate into oligodendrocytes in the brain of a knockout mouse model of Canavan disease.
    Surendran S; Shihabuddin LS; Clarke J; Taksir TV; Stewart GR; Parsons G; Yang W; Tyring SK; Michals-Matalon K; Matalon R
    Brain Res Dev Brain Res; 2004 Oct; 153(1):19-27. PubMed ID: 15464214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical localization of aspartoacylase in the rat central nervous system.
    Madhavarao CN; Moffett JR; Moore RA; Viola RE; Namboodiri MA; Jacobowitz DM
    J Comp Neurol; 2004 May; 472(3):318-29. PubMed ID: 15065127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible genotype-phenotype correlations in children with mild clinical course of Canavan disease.
    Tacke U; Olbrich H; Sass JO; Fekete A; Horvath J; Ziyeh S; Kleijer WJ; Rolland MO; Fisher S; Payne S; Vargiami E; Zafeiriou DI; Omran H
    Neuropediatrics; 2005 Aug; 36(4):252-5. PubMed ID: 16138249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canavan disease: studies on the knockout mouse.
    Matalon R; Michals-Matalon K; Surendran S; Tyring SK
    Adv Exp Med Biol; 2006; 576():77-93; discussion 361-3. PubMed ID: 16802706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical MRI findings in Canavan disease: a patient with a mild course.
    Yalcinkaya C; Benbir G; Salomons GS; Karaarslan E; Rolland MO; Jakobs C; van der Knaap MS
    Neuropediatrics; 2005 Oct; 36(5):336-9. PubMed ID: 16217711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of aspartoacylase activity disrupts survival and differentiation of neural progenitors and oligodendrocytes in a mouse model of Canavan disease.
    Kumar S; Biancotti JC; Matalon R; de Vellis J
    J Neurosci Res; 2009 Nov; 87(15):3415-27. PubMed ID: 19739253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canavan disease: a white matter disorder.
    Kumar S; Mattan NS; de Vellis J
    Ment Retard Dev Disabil Res Rev; 2006; 12(2):157-65. PubMed ID: 16807907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.
    Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B
    J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
    von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
    Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.